来自患者的有机体可告知肝癌中的药物基因组脆弱性
Alissa Michelle Wong1, Hao Huang2, Aikha Melissa Wong1
1Department of Surgery, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
JHEP reports : innovation in hepatology
|June 30, 2025
概括
使用减少生长因子的优化患者衍生瘤器官 (PDTO) 改善肝细胞癌精密医学. 这种方法有助于识别药物点,并在案例研究中显示出明确的患者生存益处.
科学领域:
- 在瘤学瘤学.
- 翻译医学是一种翻译医学.
- 基因组学就是基因组学.
背景情况:
- 患者衍生瘤器官 (PDTO) 为临床前癌症研究提供了一个有前途的模型.
- 目前PDTO面临的挑战包括培养成功,成本,标准化和时间,限制了精准医学中的临床实用性.
- 优化PDTO建立对于推进个性化癌症疗法至关重要.
研究的目的:
- 为了优化PDTO建立使用增长因子减少 (GF-) 媒体用于肝细胞癌 (HCC).
- 确定体质变异指标,以提高FDA批准的抗HCC药物疗效.
- 发现无药可治疗的HCC突变的合成致命标,并评估PDTO在个性化治疗中的可行性.
主要方法:
- 建立了23个HCC PDTO,使用GF减小的中介协议.
- 进行了全面的分析:特征突变,基因组异质性,转录组学和组织学.
- 进行了100种药物重用屏幕,药物基因组分析和合成致死性验证.
主要成果:
- 来自GF的PDTOs准确地模仿了HCC组织学和遗传异质性.
- 很少有FDA批准的药物 (<5%) 与HCC驱动突变相关.
- 通过RPS6KA3向确定CTNNB1-突变HCC中的Ceritinib敏感性,在PDTO病例研究中验证,显示生存益处.
结论:
- 使用最小GF介质建立的PDTO是精密瘤学的宝贵工具.
- 这项研究表明PDTO在指导个性化HCC治疗和改善患者存活率方面的临床实用性.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


